ClinicalTrials.gg
TerminatedNCT05840510Updated Apr 25, 2025

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

A Phase 1 interventional study of Adagrasib and nab-Sirolimus in Solid Tumor, Adult, NSCLC and Advanced Cancer, sponsored by Mirati Therapeutics Inc.. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Why this study was terminated
Business objectives have changed

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 1 of them phase 3. Neoplasm Metastasis · Bristol-Myers Squibb.

Enrollment
42nd of 44
6 · median 66
Started
2023
with 1 other
Phase 1
16 of 50
none open now
Registered
48th of 50
by date

Among the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, this one is the 42nd largest by enrollment of the 44 interventional ones that give a count, is one of 2 that started in 2023, is one of 16 in phase 1, and was the 48th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.

Read the detailed description

This study will evaluate the safety and tolerability and clinical activity of adagrasib in combination with nab-sirolimus in patients with advanced solid tumors harboring a KRAS G12C mutation.

The Phase 1 portion will enroll advanced solid tumors to establish the maximum tolerated dose (MTD) and/or to identify recommended Phase 2 combinatorial doses. The Phase 2 portion will enroll patients with NSCLC to further evaluate the safety/tolerability and clinical activity.

Adagrasib is an orally available small molecule inhibitor of KRAS G12C. nab-Sirolimus is a nanoparticle albumin-bound (nab) form of sirolimus, and sirolimus is an inhibitor of mechanistic target of rapamycin kinase (mTOR, previously known as mammalian target of rapamycin).

03

Conditions studied

  • Solid Tumor, Adult
  • NSCLC
  • Advanced Cancer
  • Metastatic Cancer
  • Malignant Neoplastic Disease

Keywords

  • KRAS
  • NSCLC
  • Adagrasib
  • KRAS G12C
  • mTOR
  • nab-sirolimus
  • Fyarro
  • ABI-009
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of solid tumor (Phase 1) or NSCLC (Phase 2) with KRAS G12C mutation
  • Unresectable or disease
  • No available treatment with curative intent
  • Adequate organ function
  • per 1.1.

Exclusion criteria

Exclusion Criteria:

  • History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
  • History of interstitial lung disease or radiation pneumonitis requiring treatment, or any evidence of clinically active interstitial lung disease or pneumonitis
  • Cardiac abnormalities
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Dose Escalation and Clinical Efficacy

    Dose escalation of adagrasib and nab-Sirolimus to determine maximum tolerated dose in combination and evaluate the clinical efficacy of adagrasib in combination with nab-sirolimus in patients with solid tumors (Phase 1) and NSCLC (Phase 2) harboring a KRAS G12C mutation

    Drug: Adagrasib · Drug: nab-Sirolimus

Interventions

  • KRAS G12C inhibitor

    Also known as: MRTX849, Krazati

  • mTOR inhibitor

    Also known as: ABI -009, Fyarro

06

What researchers measure

Primary outcomes

  1. Phase 1: Safety and tolerability in the study population.

    Safety characterized by the following, as noted from first dose of study treatment to 28 days after last dose of study treatment: 1. Type, incidence, severity, timing, seriousness and relationship to study treatment of Adverse Events 2. Laboratory abnormalities, as measured by changes in lab results such as hematologic or chemistry parameters while on study treatment 3. Number of patients modifying or discontinuing study treatment due to an AE

    Time frame: 30 months

  2. Phase 1: Maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D)

    Evaluate safety and assess number of patients with dose-limiting toxicity to determine the MTD/RP2D.

    Time frame: 30 months

  3. Phase 2: Objective Response Rate (ORR) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) (Phase 2)

    ORR evaluation of subjects treated with adagrasib in combination with nab-sirolimus in patients with NSCLC with KRAS G12C mutation (Study Population) will be completed. Objective response is the proportion of subjects that experience confirmed complete response (CR) or partial response (PR) based on RECIST v1.1 during the time period from first dose of study treatment until last dose of study treatment.

    Time frame: 30 months

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    AUC - nab-sirolimus and adagrasib

    Time frame: Up to 7 days

  2. Time to achieve maximal plasma concentration

    Tmax - nab-sirolimus and adagrasib

    Time frame: Up to 1 days

  3. Maximum observed plasma concentration

    Cmax - nab-sirolimus and adagrasib

    Time frame: Up to 1 days

  4. Terminal elimination half-life

    t1/2 - nab-sirolimus

    Time frame: Up to 7 days

  5. Phase 1 and 2: Evaluate efficacy endpoints characterized by overall survival, progression-free survival, and duration of response in the study population.

    1. Overall survival is defined as time from date of randomization to date of death due to any cause. 2. Progression-free survival is defined as the time from randomization to the date of Progressive Disease (PD) or death due to any cause,whichever occurs first. 3. Duration of response defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either PD or death due to any cause, whichever occurs first.

    Time frame: 30 months

  6. Phase 1: Objective Response Rate (ORR) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

    ORR evaluation of subjects treated with adagrasib in combination with nab-sirolimus in patients with advanced solid tumors and NSCLC with KRAS G12C mutation (Study Population) will be completed. Objective response is the proportion of subjects that experience confirmed complete response (CR) or partial response (PR) based on RECIST v1.1 during the time period from first dose of study treatment until last dose of study treatment.

    Time frame: 30 months

  7. Phase 2: Safety and tolerability in the study population.

    Safety characterized by the following, as noted from first dose of study treatment to 28 days after last dose of study treatment: 1. Type, incidence, severity, timing, seriousness and relationship to study treatment of Adverse Events 2. Laboratory abnormalities, as measured by changes in lab results such as hematologic or chemistry parameters while on study treatment 3. Number of patients modifying or discontinuing study treatment due to an AE,

    Time frame: 30 months

07

Study locations

3 sites
  • Local Institution - 019-104
    Cleveland, Ohio 44121, United States
  • Local Institution - 019-101
    Nashville, Tennessee 37203, United States
  • Local Institution - 019-102
    Houston, Texas 77030-4000, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Dec 2024, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
May 3, 2023
StartActual
Aug 7, 2023
Primary completionActual
Dec 27, 2024
CompletionActual
Dec 27, 2024
Last update
Apr 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05840510
Collaborators
Aadi Bioscience, Inc.
Responsible party
Sponsor
First posted
May 3, 2023
Start date
Aug 7, 2023
Primary completion
Dec 27, 2024
Completion
Dec 27, 2024
Last update
Apr 25, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adagrasib · Sirolimus Albumin-bound Nanoparticles

Start the discussion